Vutrisiran is a chemically synthesized small interfering RNA (siRNA) therapeutic designed to reduce the production of transthyretin (TTR). It is supplied as vutrisiran sodium and belongs to the class of RNA-based therapeutic active pharmaceutical ingredients.
Vutrisiran works through RNA interference. After administration, the siRNA component is delivered predominantly to the liver, where it interacts with the cellular RNA-induced silencing complex and promotes degradation of TTR messenger RNA. This reduces the production of transthyretin protein and subsequently decreases the formation of transthyretin amyloid deposits.
Vutrisiran sodium is a highly specialized oligonucleotide drug substance. It consists of a double-stranded siRNA sequence containing chemically modified nucleotides and a ligand containing three N-acetylgalactosamine (GalNAc) residues.
The EMA describes vutrisiran as a synthetic double-stranded siRNA targeted against transthyretin mRNA. Its backbone contains phosphorothioate linkages, while the nucleotide sequence incorporates 2′-fluoro and 2′-O-methyl modifications. The GalNAc ligand enables targeted delivery of the siRNA to hepatocytes.
Vutrisiran is structurally different from conventional chemical APIs because its molecular identity depends on the complete nucleotide sequence, chemical modifications, duplex structure and GalNAc conjugation.
FDA substance records identify Vutrisiran under UNII GB4I2JI8UI and associate it with CAS 1867157-35-4.
The sodium form has a very high molecular mass compared with conventional pharmaceutical molecules because it contains two oligonucleotide strands together with the GalNAc conjugate and sodium counterions.
Vutrisiran uses the RNA interference pathway to selectively reduce TTR messenger RNA. The active siRNA is designed to recognize TTR mRNA inside hepatocytes.
Following sequence-specific binding, TTR mRNA is degraded, reducing the amount of transthyretin protein produced by the liver. This mechanism reduces circulating TTR and is intended to decrease the formation and accumulation of transthyretin amyloid.
A major feature of Vutrisiran is its triantennary GalNAc conjugate.
GalNAc binds to the asialoglycoprotein receptor expressed on hepatocytes. This provides targeted delivery of the siRNA to the liver and allows the therapeutic molecule to enter hepatocytes efficiently.
The GalNAc conjugation is therefore a critical quality attribute of Vutrisiran and must be appropriately characterized during drug-substance manufacturing and quality control.
Vutrisiran is produced through a specialized oligonucleotide manufacturing process involving controlled synthesis of the individual strands, chemical modification, purification, duplex formation and conjugation.
Because the API is an siRNA molecule, manufacturing controls extend beyond conventional chemical purity. The complete nucleotide sequence, molecular mass, duplex formation, chemical modifications, purity profile and conjugate identity are important characteristics of the final drug substance.
Vutrisiran requires specialized analytical methods for comprehensive characterization.
Analytical techniques used for Vutrisiran include IP-HPLC, LC-MS, MS/MS sequencing, UV spectroscopy, FT-IR, NMR, thermal analysis and Tm determination.
EMA reports evaluation of duplex purity using non-denaturing IPRP-HPLC, assay by UV and purity using denaturing AX-HPLC and IPRP-UPLC. Water content and pH are also included among the evaluated quality attributes.
For an siRNA API such as Vutrisiran, impurity control involves more than a conventional single HPLC purity number. Manufacturing and analytical programs evaluate truncated sequences, modified or degraded oligonucleotide species, duplex-related impurities and other process-related substances.
Both denaturing and non-denaturing chromatographic techniques can provide information about the integrity and purity of the oligonucleotide drug substance.
The duplex structure of Vutrisiran can be evaluated through thermal melting temperature (Tm) analysis. Tm is useful for evaluating duplex formation and structural consistency.
Thermal and forced-degradation studies are also important for understanding the stability of an oligonucleotide API. EMA reports thermal, acidic, basic, oxidative and photolytic stress studies for Vutrisiran.
Vutrisiran sodium is a highly specialized oligonucleotide material, and water content is an important quality attribute. EMA identifies hygroscopicity as a property that can influence handling and concentration during drug-product manufacturing.
The active substance is freely soluble in water, which allows it to be formulated as an aqueous injectable solution.
Vutrisiran is the active substance in Amvuttra. EMA currently lists Amvuttra as containing vutrisiran sodium and identifies vutrisiran as the active substance.
The medicine is used in adults with hereditary transthyretin-mediated amyloidosis with stage 1 or stage 2 polyneuropathy and is also authorized for hereditary or non-hereditary ATTR amyloidosis with cardiomyopathy in the EU.
Important quality attributes for Vutrisiran include nucleotide sequence identity, molecular mass, duplex identity, duplex purity, chromatographic purity, assay, Tm, sodium content, water content, pH, residual solvents, endotoxins and microbial quality.
Because Vutrisiran is an siRNA-GalNAc conjugate, conventional CMS parameters such as melting point, residue on ignition and specific rotation are not suitable primary release tests.
Vutrisiran is a specialized RNA-based pharmaceutical API requiring advanced oligonucleotide synthesis, purification and analytical characterization.
Swapnroop Drugs & Pharmaceuticals provides pharmaceutical API-related solutions for specialized pharmaceutical development and manufacturing requirements. Vutrisiran API can be evaluated for research, analytical development and pharmaceutical manufacturing applications according to the applicable technical and regulatory requirements.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | NLT 98.0% |
| pH (1% Solution) | 6.0–8.0 |
| Individual Impurity | NMT 1.0% |
| Total Impurities | NMT 5.0% |
| Water Content | NMT 10.0% |